THE PROGNOSTIC SIGNIFICANCE OF CD10+ MUM1+ GCB SUBTYPE OF DIFFUSE LARGE B-CELL LYMPHOMAS
Main Article Content
Abstract
PURPOSE - Diffuse Large B-Cell Lymphoma can be subclassified into the prognostically distinct groups of GCB and non-GCB using the immunohistochemical Hans algorithm. However, in real life, patients classified as GCB show differing outcomes even when treated with the same chemotherapy regimen. CD10 is a GCB marker, while MUM1 is a non-GCB marker, but Hans algorithm classifies CD10+ MUM1+ patients as GCB DLBCL. We explored whether CD10+ MUM1+ GCB DLBCL patients had different outcomes compared to rest of the GCB DLBCL patients.
METHODS - In this study, we retrospectively analyzed the clinical records of 427 DLBCL patients treated with standard chemo-immunotherapy at Kidwai Memorial Institute of Oncology, Bengaluru from 2013 to 2019. The clinical characteristics, response rate and overall survival of CD10+ MUM1+ GCB group was compared with MUM1-ve GCB group and non-GCB group.
RESULTS - Among the patients studied, 187 (43%) patients were of GCB subtype, whereas 240 (57%) patients belonged to the non-GCB subtype. Additionally, 61 (14.3%) patients were of the CD10+ MUM1+ GCB immune-phenotype. No significant differences could be demonstrated in the clinical characteristics of CD10+ MUM1+ GCB and MUM1- GCB patients. Patients with CD10+ MUM1+ GCB subtype exhibited a significantly inferior response rate compared to those with MUM1- GCB subtype (81% versus 92%; p=0.04). Although, both non-GCB and CD10+ MUM1+ GCB subtypes displayed diminished overall survival in comparison to MUM1- GCB patients, (non-GCB = 33 months, CD10+ MUM1+ GCB = 33 months and MUM1-ve GCB = 40.4 months, p = 0.21) it did not reach statistical significance
CONCLUSION - CD10+ MUM1+ GCB patients may be prognostically more similar to non-GCB patients, as suggested by the inferior response rates and numerically inferior OS compared to other GCB patients. This needs further confirmation in prospective studies.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Anderson. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. International Journal of Oncology. 2009;35(05). doi:https://doi.org/10.3892/ijo_00000409
3. Ruppert AS, Dixon JG, Salles GA, et al. International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. Blood. Published online March 13, 2020.
doi:https://doi.org/10.1182/blood.2019002729
4. Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? American Society of Clinical Oncology Educational Book. 2015; (35):e449-e457. doi:https://doi.org/10.14694/edbook_am.2015.35.e449
5. Hans CP. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282. doi:https://doi.org/10.1182/blood-2003-05-1545
6. William W.L. Choi, Weisenburger DD, Greiner TC, et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clinical Cancer Research. 2009;15 (17):5494-5502. doi:https://doi.org/10.1158/1078-0432.ccr-09-0113
7. Muris J, Meijer C, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. The Journal of Pathology. 2006;208(5):714-723. doi:https://doi.org/10.1002/path.1924
8. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.
doi:https://doi.org/10.1182/blood-2013-09-524108
9. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology. 2014;32(27):3059-3067. doi:https://doi.org/10.1200/jco.2013.54.8800
10. K Benesova, K Forsterova, H Votavova, et al. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma. 2012;60 (01):68-73. doi:https://doi.org/10.4149/neo_2013_010
11. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836-4843. doi:https://doi.org/10.1182/blood-2010-12-322362
12. Eisuke Shiozawa, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leukemia research. 2007; 31(11):1579-1583. doi:https://doi.org/10.1016/j.leukres.2007.03.017
13. Ajay Gogia, Nair S, Arora S, et al. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Frontiers in oncology. 2021;11. doi:https://doi.org/10.3389/fonc.2021.770747
14. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. Clinical Lymphoma Myeloma and Leukemia. 2014;14 (6):460-467.e2. doi:https://doi.org/10.1016/j.clml.2014.05.002
15. Thunberg U, Enblad G, Berglund M. Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup. Haematologica. 2012;97(2):e3. doi:https://doi.org/10.3324/haematol.2011.057240
16. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells. Journal of Experimental Medicine. 2001;194(12): 1861-1874. doi:https://doi.org/10.1084/jem.194.12.1861
17. Kim M, Suh C, Kim J, Jung Yong Hong. Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL. Blood. 2017;130:5231-5231. doi:https://doi.org/10.1182/blood.v130.suppl_1.5231.5231
18. Castellino A, Chiappella A, LaPlant BR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer Journal. 2018;8(11):108. doi:https://doi.org/10.1038/s41408-018-0145-9
19. Younes A, Sehn LH, Johnson P, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2019;37(15):1285-1295. doi:https://doi.org/10.1200/JCO.18.02403
20. Lu TX, Miao Y, Wu JZ, et al. The distinct clinical features and prognosis of the CD10+ MUM1+ and CD10−Bcl6−MUM1− diffuse large B-cell lymphoma. Scientific Reports. 2016;6. doi:https://doi.org/10.1038/srep20465
21. Chung Che Chang, McClintock S, Cleveland RP, et al. Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma. The American Journal of Surgical Pathology. 2004;28(4):464-470. doi:https://doi.org/10.1097/00000478-200404000-00005
22. ColomoL, López-GuillermoA, PeralesM, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78-84.
doi:https://doi.org/10.1182/blood-2002-04-1286
23. Bai M, Angelos Skyrlas, Agnantis NJ, et al. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. PubMed. 2005;25(1A):347-362.